NZ749626A - Genetically modified non-human animals and methods of use thereof - Google Patents

Genetically modified non-human animals and methods of use thereof

Info

Publication number
NZ749626A
NZ749626A NZ749626A NZ74962613A NZ749626A NZ 749626 A NZ749626 A NZ 749626A NZ 749626 A NZ749626 A NZ 749626A NZ 74962613 A NZ74962613 A NZ 74962613A NZ 749626 A NZ749626 A NZ 749626A
Authority
NZ
New Zealand
Prior art keywords
genetically modified
human animal
human
activity
candidate agent
Prior art date
Application number
NZ749626A
Other languages
English (en)
Inventor
Andrew J Murphy
Richard Flavell
George D Yancopoulos
Till Strowig
Markus G Manz
Chiara Borsotti
Madhav Dhodapkar
Sean Stevens
Original Assignee
Regeneron Pharma
Institute For Res In Biomedicine Irb
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Institute For Res In Biomedicine Irb, Univ Yale filed Critical Regeneron Pharma
Publication of NZ749626A publication Critical patent/NZ749626A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ749626A 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof NZ749626A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722437P 2012-11-05 2012-11-05
NZ724353A NZ724353A (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof

Publications (1)

Publication Number Publication Date
NZ749626A true NZ749626A (en) 2023-11-24

Family

ID=49876957

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ724353A NZ724353A (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof
NZ631614A NZ631614A (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof
NZ749626A NZ749626A (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ724353A NZ724353A (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof
NZ631614A NZ631614A (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof

Country Status (19)

Country Link
US (5) US9901082B2 (enExample)
EP (5) EP4389764A3 (enExample)
JP (5) JP6422441B2 (enExample)
KR (5) KR102649893B1 (enExample)
CN (3) CN114766432B (enExample)
AU (3) AU2013337242B2 (enExample)
CA (1) CA2887706C (enExample)
DK (4) DK3939423T3 (enExample)
ES (4) ES2748662T3 (enExample)
FI (1) FI3939423T3 (enExample)
IL (5) IL311744B2 (enExample)
MX (3) MX370856B (enExample)
MY (1) MY175400A (enExample)
NO (1) NO2946162T3 (enExample)
NZ (3) NZ724353A (enExample)
PT (4) PT3939423T (enExample)
RU (1) RU2673156C2 (enExample)
SG (2) SG10201707449TA (enExample)
WO (1) WO2014071397A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
RU2642319C2 (ru) * 2012-09-07 2018-01-24 Йель Юниверсити Генетически модифицированные, не принадлежащие к человеческому роду животные и способ их использования
PT3939423T (pt) 2012-11-05 2024-05-29 Regeneron Pharma Animais não humanos geneticamente modificados e métodos de utilização dos mesmos
EP3543253B1 (en) 2013-02-20 2024-03-27 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
SI3138397T1 (sl) 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
US20150143558A1 (en) 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
MX358206B (es) 2013-11-19 2018-08-09 Regeneron Pharma Animales no humanos que tienen un gen humanizado de un ligando inductor de la proliferacion.
DK3129400T3 (da) 2014-04-08 2020-06-08 Regeneron Pharma Ikke-humane dyr med humaniserede Fc-gamma-receptorer
CN111647627A (zh) 2014-04-28 2020-09-11 重组股份有限公司 多重基因编辑
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
MX379268B (es) * 2014-05-19 2025-03-11 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
SMT202000184T1 (it) 2014-06-19 2020-05-08 Regeneron Pharma Animali non umani aventi un gene 1 della morte cellulare programmata umanizzato
EP3223605B9 (en) 2014-11-24 2021-08-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized cd3 complex
HUE064960T2 (hu) * 2014-12-05 2024-04-28 Regeneron Pharma Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok
AU2015360667B2 (en) 2014-12-09 2021-09-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
WO2016137841A1 (en) * 2015-02-26 2016-09-01 William Paterson University Of New Jersey Transgenic mice
WO2016164492A2 (en) 2015-04-06 2016-10-13 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
CN107896479B (zh) * 2015-04-13 2021-07-13 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法
EP3376857B1 (en) 2015-11-20 2021-02-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
PT3422845T (pt) 2016-02-29 2021-08-26 Regeneron Pharma Roedores com um gene tmprss humanizado
KR20190038613A (ko) * 2016-08-11 2019-04-08 더 잭슨 래보라토리 유전자 변형된 면역결핍 비-인간 동물에서의 개선된 인간 적혈구 생존에 관한 방법 및 조성물
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
JP7458185B2 (ja) * 2016-11-30 2024-03-29 ザ ジャクソン ラボラトリー 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル
CA3053386A1 (en) * 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Non-human animal models of retinoschisis
CN107115424B (zh) * 2017-05-09 2018-05-29 江西樟树市正康医药生物科技有限公司 改变酸性体质保钙及清热解毒的中药组合物及制备方法
JP7129426B2 (ja) 2017-05-12 2022-09-01 ザ ジャクソン ラボラトリー Ｍｈｃクラスｉおよびｍｈｃクラスｉｉを欠損しているｎｓｇマウス
EP4276185A3 (en) 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
US11712026B2 (en) 2017-10-18 2023-08-01 The Jackson Laboratory Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
CN111655031B (zh) 2017-11-30 2022-11-18 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
MA52091A (fr) 2018-03-21 2021-01-27 Alx Oncology Inc Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
US11589562B2 (en) 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111057721B (zh) * 2018-10-12 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用
CN111172190B (zh) * 2018-12-25 2021-07-30 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf2基因改造非人动物的构建方法及应用
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
KR20220016869A (ko) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
BR112021022722A2 (pt) 2019-06-07 2022-01-04 Regeneron Pharma Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
US20220354098A1 (en) * 2019-07-17 2022-11-10 Yale University Genetically Modified Non-Human Animals and Methods of Use Thereof
CN111304246B (zh) * 2019-12-17 2021-05-04 百奥赛图江苏基因生物技术有限公司 一种人源化细胞因子动物模型、制备方法及应用
JP7600245B2 (ja) * 2020-01-10 2024-12-16 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド ヒト又はキメラｍｈｃタンパク質複合体を有する遺伝子組換え非ヒト動物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP4216971A4 (en) 2020-09-24 2024-10-02 The Jackson Laboratory HUMANIZED MOUSE MODELS FOR EVALUATING CELLULAR IMMUNOTHERAPY
CN118511853A (zh) 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
CN116918767A (zh) * 2022-04-07 2023-10-24 上海立迪生物技术股份有限公司 一种人all小鼠原位pdox模型的建立方法及应用
CN116918766A (zh) * 2022-04-07 2023-10-24 上海立迪生物技术股份有限公司 一种人aml小鼠原位pdox模型的建立方法及应用
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
AU2024304358A1 (en) 2023-06-16 2025-11-06 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2025250495A1 (en) * 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1988003173A2 (en) 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
EP0322240B1 (en) 1987-12-23 1995-03-01 The Board Of Trustees Of The Leland Stanford Junior University Chimeric immunocompromised mammals and their use
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
JP2935511B2 (ja) * 1989-10-20 1999-08-16 忠三 岸本 ヒトｉｌ―６レセプターの製造方法
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DK0438053T3 (da) 1990-01-15 1999-11-22 Yeda Res & Dev Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr
AU637914B2 (en) 1990-05-03 1993-06-10 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
EP0484512A4 (en) 1990-05-25 1993-05-05 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0571525A1 (en) 1991-02-11 1993-12-01 OMMAYA, Ayub K. Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
DE69229254T2 (de) 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
CA2103693A1 (en) 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
CA2195678A1 (en) 1994-07-27 1996-02-08 Joseph A. Borkowski Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
CA2284689C (en) 1997-04-09 2009-10-06 Lung-Ji Chang Animal model for evaluation of vaccines
GB2337755B (en) * 1998-05-29 2003-10-29 Secr Defence Virus vaccine
WO2001015521A1 (en) 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
CA2392740A1 (en) * 1999-12-09 2001-06-14 Human Genome Sciences, Inc. Il-6 like polynucleotides, polypeptides, and antibodies
US6864061B2 (en) 2000-09-14 2005-03-08 Genetrol Biotherapeutics, Inc. Method for screening compounds for anti-inflammatory activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
BR0211079A (pt) * 2001-07-10 2005-08-30 Johnson & Johnson Res Pty Ltd Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas
US20030124091A1 (en) * 2001-10-26 2003-07-03 Large Scale Biology Corporation Endothelial cell derived hematopoietic growth factor
EP1994824A1 (en) 2001-11-15 2008-11-26 Kirin Pharma Kabushiki Kaisha Chimeric non-human animal
WO2004005496A1 (ja) 2002-07-05 2004-01-15 Kirin Beer Kabushiki Kaisha 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
AU2003278790A1 (en) 2002-09-09 2004-03-29 California Institute Of Technology Methods and compositions for the generation of humanized mice
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
KR20050084317A (ko) 2002-12-16 2005-08-26 제넨테크, 인크. 인간 ｃｄ２０ 및(또는) ｃｄ１６을 발현하는 트랜스제닉마우스
CA2515288A1 (en) * 2003-03-12 2004-09-23 Genentech, Inc. Compositions with hematopoietic and immune activity
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
PT2019683T (pt) 2006-04-25 2017-03-17 Univ California Administração de fatores de crescimento para o tratamento de distúrbios do snc
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
EP2088854A1 (en) 2006-12-05 2009-08-19 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
JP5666903B2 (ja) 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 導入遺伝子の発現を増強するための方法および組成物
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
WO2009042917A1 (en) 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
WO2009097468A2 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
WO2010119039A1 (en) * 2009-04-13 2010-10-21 Apceth Gmbh & Co. Kg Engineered mesenchymal stem cells and method of using same to treat tumors
SG176117A1 (en) 2009-06-29 2011-12-29 Ilya B Leskov Non-human mammal model of human hematopoietic cancer
EP2449094A4 (en) * 2009-06-29 2013-07-10 Qingfeng Chen METHOD FOR PRODUCING HUMANIZED NON-MAMMAL MAMMALS
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
SG10201408415PA (en) * 2009-12-21 2015-01-29 Regeneron Pharma HUMANIZED FCγ R MICE
WO2012040207A2 (en) 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
BR112014008529A2 (pt) * 2011-10-28 2017-04-18 Regeneron Pharma il-6 humanizado e receptor de il-6
RU2642319C2 (ru) 2012-09-07 2018-01-24 Йель Юниверсити Генетически модифицированные, не принадлежащие к человеческому роду животные и способ их использования
PT3939423T (pt) 2012-11-05 2024-05-29 Regeneron Pharma Animais não humanos geneticamente modificados e métodos de utilização dos mesmos
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
SI3138397T1 (sl) 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
MX379268B (es) 2014-05-19 2025-03-11 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
CN107896479B (zh) 2015-04-13 2021-07-13 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法

Also Published As

Publication number Publication date
JP7579304B2 (ja) 2024-11-07
IL299887B2 (en) 2024-09-01
NO2946162T3 (enExample) 2018-06-09
DK3308641T3 (da) 2019-10-07
KR20240042142A (ko) 2024-04-01
CN104918483A (zh) 2015-09-16
JP7105844B2 (ja) 2022-07-25
KR20220075242A (ko) 2022-06-07
NZ631614A (en) 2016-10-28
AU2022200302B2 (en) 2025-04-10
IL270124B1 (enExample) 2023-02-01
WO2014071397A2 (en) 2014-05-08
KR102458016B1 (ko) 2022-10-25
IL238478B (en) 2018-05-31
MX2015005654A (es) 2016-04-28
IL311744B1 (en) 2025-06-01
CA2887706C (en) 2022-08-02
KR20210087567A (ko) 2021-07-12
EP3308641A1 (en) 2018-04-18
US20180049413A1 (en) 2018-02-22
IL258968A (en) 2018-06-28
IL311744B2 (en) 2025-10-01
IL258968B (en) 2019-10-31
CN114766432B (zh) 2024-08-02
KR20150081285A (ko) 2015-07-13
KR20220148307A (ko) 2022-11-04
MX2020012427A (es) 2022-06-08
EP3556206A1 (en) 2019-10-23
JP2015534819A (ja) 2015-12-07
EP3939423A1 (en) 2022-01-19
EP3308641B1 (en) 2019-07-03
US20240099278A1 (en) 2024-03-28
IL311744A (en) 2024-05-01
CN108401987B (zh) 2022-04-29
IL270124B2 (en) 2023-06-01
ES2983031T3 (es) 2024-10-21
EP2914102A2 (en) 2015-09-09
PT3939423T (pt) 2024-05-29
US11778995B2 (en) 2023-10-10
KR102275412B1 (ko) 2021-07-12
CA2887706A1 (en) 2014-05-08
US20160366862A1 (en) 2016-12-22
EP4389764A3 (en) 2024-08-14
DK2914102T3 (en) 2017-12-11
PT3556206T (pt) 2021-08-24
ES2748662T3 (es) 2020-03-17
CN108401987A (zh) 2018-08-17
KR102768101B1 (ko) 2025-02-18
US9986724B2 (en) 2018-06-05
RU2015121195A (ru) 2016-12-27
AU2013337242A1 (en) 2015-04-30
NZ724353A (en) 2022-05-27
AU2019204775B2 (en) 2021-10-21
HK1210380A1 (en) 2016-04-22
IL238478A0 (en) 2015-06-30
PT3308641T (pt) 2019-10-24
JP2019037238A (ja) 2019-03-14
JP6772234B2 (ja) 2020-10-21
ES2884598T3 (es) 2021-12-10
WO2014071397A3 (en) 2014-06-26
JP2025010204A (ja) 2025-01-20
JP6422441B2 (ja) 2018-11-14
RU2018140189A (ru) 2018-12-10
IL299887B1 (en) 2024-05-01
KR102402806B1 (ko) 2022-05-30
EP3939423B1 (en) 2024-03-06
AU2013337242B2 (en) 2019-04-04
DK3556206T3 (da) 2021-08-09
MY175400A (en) 2020-06-24
IL270124A (enExample) 2019-12-31
EP3556206B1 (en) 2021-06-02
US20210100228A1 (en) 2021-04-08
RU2018140189A3 (enExample) 2022-05-04
MX370856B (es) 2020-01-08
FI3939423T3 (fi) 2024-05-23
IL299887A (en) 2023-03-01
CN114766432A (zh) 2022-07-22
EP2914102B1 (en) 2017-10-18
US9901082B2 (en) 2018-02-27
SG11201502685XA (en) 2015-05-28
DK3939423T3 (da) 2024-05-06
JP2022132376A (ja) 2022-09-08
MX377561B (es) 2025-03-10
HK1253909A1 (en) 2019-07-05
AU2019204775A1 (en) 2019-07-25
MX2019015882A (es) 2020-02-07
ES2655442T3 (es) 2018-02-20
RU2673156C2 (ru) 2018-11-22
US20140134662A1 (en) 2014-05-15
PT2914102T (pt) 2018-01-15
SG10201707449TA (en) 2017-10-30
AU2022200302A1 (en) 2022-02-10
EP4389764A2 (en) 2024-06-26
JP2021010371A (ja) 2021-02-04
CN104918483B (zh) 2018-05-11
KR102649893B1 (ko) 2024-03-25
US10785968B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
NZ749626A (en) Genetically modified non-human animals and methods of use thereof
WO2012040207A3 (en) HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2011005978A3 (en) Methods of manipulating cell signaling
NZ717647A (en) Structure based predictive modeling
NZ704957A (en) Genetically modified non-human animals and methods of use thereof
BR112014009075A2 (pt) método para fornecer uma solução de eletrólito, e, sistema de bateria de célula de fluxo
BR112016011004A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
MX2013007650A (es) Metodo de cultivo de celulas animales.
EA201391465A1 (ru) Система и способ характеризации неопределенности оценки пласта коллектора
WO2008102602A1 (ja) Ｂｌａｓｔｏｃｙｓｔ ｃｏｍｐｌｅｍｅｎｔａｔｉｏｎを利用した臓器再生法
HUE037001T2 (hu) Eljárás egy adott metabolitot a megfelelõ vad típushoz képest megnövelt koncentrációban tartalmazó sejt azonosítására, ahol a sejt rekombináns mérnökség (rekombineering) révén van módosítva; eljárás egy adott metabolit optimális termelésével bíró, genetikailag módosított sejt elõállítására; eljárás az említett metabolit és a megfelelõ nukleinsavak elõállítására
GB201105450D0 (en) Improvements in and relating to methods and systems for investigating radioactive sources in locations
CL2013003821A1 (es) Polinucleótido que codifica un polipéptido receptor pyr/pyl mutado, casete de expresión que comprende dicho ácido nucleico, y método para producir planta con actividad inhibida de la proteína fosfatasa tipo 2 en ausencia de ácido abscísico.
ATE499598T1 (de) Markierungsfreier einzelzelltest
WO2009099590A3 (en) Psoriatic phenotype mice, cell lines, treatments, and methods
NZ720244A (en) Methods of feeding fish fermentation cell mass
RU2011135856A (ru) Способ диагностики технического состояния энергетического оборудования
山村宗正 Establishment and analysis of a new inbred strain of mice spontaneously developing tarsal ankylosis by selective breeding based on ankylosis-related phenotype
EP2801620A4 (en) DEVELOPMENT OF A SIMPLE DISTINCTION PROCESS FOR EMBRYONIC STEM CELLS AND IPS CELLS OF LOW QUALITY AS INDICATORS FOR THE BIOLOGICAL CLOCK AND DEVELOPMENT OF A CELL EVALUATION PROCESS AS A BIOLOGICAL CLOCK INDICATOR
UA54214U (ru) Способ определения предрасположенности к пародонтиту в эксперименте
UA60528U (ru) Способ исследования дыхания митохондрий in situ
UA52652U (ru) Способ оценки линейного развития скота
Worthy et al. Decision-Making in Older Adults: Sometimes Older is Wiser
UA57657U (ru) Способ оценки степени отрицательного влияния нитратов и нитритов ha состояние антиоксидантной защиты организма молодняка крупного рогатого ckota
CY1117310T1 (el) Ανθρωπινα υποβοηθητικα κυτταρα και χρησεις αυτων

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 05 NOV 2026 BY GRIFFITH HACK

Effective date: 20240613